<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04909918</url>
  </required_header>
  <id_info>
    <org_study_id>17300610</org_study_id>
    <nct_id>NCT04909918</nct_id>
  </id_info>
  <brief_title>Impact of Steroids on Inflammatory Response in Covid-19</brief_title>
  <official_title>The Impact of Dexamethasone Versus Methylprednisolone Upon Neutrophil/Lymphocyte Ratio (NLR) in COVID-19 Diseased Patients Admitted in ICU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      we designed this study to observe the efficacy and safety of dexamethasone versus&#xD;
      methylprednisolone in covid-19 diseased patients upon monitoring the inflammatory response&#xD;
      and to compare the outcome when these steroids will be given in covid-19 diseased patients in&#xD;
      our ICU.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A written informed consent will be taken from the patients or their relatives. The study will&#xD;
      involve adults (age 18-no limit years) who will be diagnosed covid-19 with destructive&#xD;
      inflammatory immune response needing ICU admission to be run on steroid therapy.&#xD;
&#xD;
      Patients will be assigned randomly to two groups (30 subjects each). The study drug will be&#xD;
      delivered in opaque bags labeled &quot;study drug&quot; and in (Group D) intravenous dexamethasone 8&#xD;
      mg/day given for 7 days, in (Group M) intravenous methylprednisolone 1 mg/kg/day in 2 divided&#xD;
      doses per day given for 7 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 28, 2021</start_date>
  <completion_date type="Actual">August 20, 2021</completion_date>
  <primary_completion_date type="Actual">August 15, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neutrophil/lymphocyte ratio (NLR)</measure>
    <time_frame>7 days</time_frame>
    <description>Monitoring of systemic inflammation by follow up of neutrophil/lymphocyte ratio (NLR) at days 0, 48 hour, 72 hour and at day 7 between the two study drugs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6 (IL-6) level</measure>
    <time_frame>7days</time_frame>
    <description>Serum level of IL-6 is taken before start drug study &amp;at 7 days to assess inflammatory and immune response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (CRP) test</measure>
    <time_frame>3 days</time_frame>
    <description>CRP test is done before start drug study, at 48hour and 72 hour to assess inflammatory response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial oxygen tension/ inspired oxygen fraction (P/F ratio)</measure>
    <time_frame>3 days</time_frame>
    <description>Assessing p/f ratio from arterial blood gas to monitor oxygenation &amp; need for upgrading of oxygen, this is monitored before start of study drugs,at 48 hour and 72 hour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU stay</measure>
    <time_frame>7 days</time_frame>
    <description>Period of patients admission in the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>7days</time_frame>
    <description>Short-term icu mortality (7 days) for patients will be expired</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>(Group D )Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous dexamethasone 8 mg/day given for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(Group M) methylprednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous methylprednisolone 1 mg/kg/day in 2 divided doses per day given for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Baseline laboratory &amp; clinical data will be taken before and after the study drugs according to our protocol.Intravenous dexamethasone 8 mg/day given for 7 days</description>
    <arm_group_label>(Group D )Dexamethasone</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Baseline laboratory &amp; clinical data will be taken before and after the study drugs according to our protocol. Intravenous methylprednisolone 1 mg/kg/day in 2 divided doses per day given for 7 days</description>
    <arm_group_label>(Group M) methylprednisolone</arm_group_label>
    <other_name>Solu-medrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (age 18-no limit years) who will be diagnosed covid-19&#xD;
&#xD;
          -  With destructive inflammatory immune response needing ICU admission to be run on&#xD;
             steroid therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe immunosuppression like HIV (Human immunodeficiency Virus)&#xD;
&#xD;
          -  Long term use of immunosuppressant for any other chronic illness&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Patients who are on chronic use of corticosteroids like asthma, rheumatoid arthritis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omar Soliman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assiut university hospital</name>
      <address>
        <city>Assiut</city>
        <state>Assuit</state>
        <zip>Assuit universi</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Polidoro RB, Hagan RS, de Santis Santiago R, Schmidt NW. Overview: Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19. Front Immunol. 2020 Jun 26;11:1626. doi: 10.3389/fimmu.2020.01626. eCollection 2020. Review.</citation>
    <PMID>32714336</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 30, 2021</study_first_submitted>
  <study_first_submitted_qc>May 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>September 4, 2021</last_update_submitted>
  <last_update_submitted_qc>September 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Omar Makram Soliman</investigator_full_name>
    <investigator_title>Lecturer of anesthesia and ICU</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

